Literature DB >> 12920424

Adverse drug reactions to oxycodone and hydrocodone in CYP2D6 ultrarapid metabolizers.

Jose de Leon, Lori Dinsmore, Peter Wedlund.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2003        PMID： 12920424     DOI： 10.1097/01.jcp.0000085421.74359.60

Source DB:  PubMed          Journal:  J Clin Psychopharmacol        ISSN： 0271-0749            Impact factor:   3.153


× No keyword cloud information.
  17 in total

Review 1.  The AmpliChip CYP450 genotyping test: Integrating a new clinical tool.

Authors:  Jose de Leon; Margaret T Susce; Elaina Murray-Carmichael
Journal:  Mol Diagn Ther       Date:  2006       Impact factor: 4.074

2.  Genetic polymorphisms and drug interactions modulating CYP2D6 and CYP3A activities have a major effect on oxycodone analgesic efficacy and safety.

Authors:  C F Samer; Y Daali; M Wagner; G Hopfgartner; C B Eap; M C Rebsamen; M F Rossier; D Hochstrasser; P Dayer; J A Desmeules
Journal:  Br J Pharmacol       Date:  2010-06       Impact factor: 8.739

3.  Novel drug metabolism indices for pharmacogenetic functional status based on combinatory genotyping of CYP2C9, CYP2C19 and CYP2D6 genes.

Authors:  David Villagra; John Goethe; Harold I Schwartz; Bonnie Szarek; Mohan Kocherla; Krystyna Gorowski; Andreas Windemuth; Gualberto Ruaño
Journal:  Biomark Med       Date:  2011-08       Impact factor: 2.851

4.  CYP2D6 pharmacogenetic and oxycodone pharmacokinetic association study in pediatric surgical patients.

Authors:  Rajiv Balyan; Marc Mecoli; Raja Venkatasubramanian; Vidya Chidambaran; Nichole Kamos; Smokey Clay; David L Moore; Jagroop Mavi; Chris D Glover; Peter Szmuk; Alexander Vinks; Senthilkumar Sadhasivam
Journal:  Pharmacogenomics       Date:  2017-02-17       Impact factor: 2.533

5.  Polymorphism of human cytochrome P450 2D6 and its clinical significance: part II.

Authors:  Shu-Feng Zhou
Journal:  Clin Pharmacokinet       Date:  2009       Impact factor: 6.447

6.  Composite functional genetic and comedication CYP2D6 activity score in predicting tamoxifen drug exposure among breast cancer patients.

Authors:  Silvana Borges; Zeruesenay Desta; Yan Jin; Azzouz Faouzi; Jason D Robarge; Sanosh Philips; Santosh Philip; Anne Nguyen; Vered Stearns; Daniel Hayes; James M Rae; Todd C Skaar; David A Flockhart; Lang Li
Journal:  J Clin Pharmacol       Date:  2010-01-15       Impact factor: 3.126

Review 7.  Cytochrome P450-mediated changes in oxycodone pharmacokinetics/pharmacodynamics and their clinical implications.

Authors:  Karin C Söderberg Löfdal; Marine L Andersson; Lars L Gustafsson
Journal:  Drugs       Date:  2013-05       Impact factor: 9.546

Review 8.  [Differential therapeutic aspects of analgesia with oral sustained-release strong opioids: application intervals, metabolism and immunosuppression].

Authors:  K Güttler; R Sabatowski
Journal:  Schmerz       Date:  2008-10       Impact factor: 1.107

9.  Voriconazole drastically increases exposure to oral oxycodone.

Authors:  Nora M Hagelberg; Tuija H Nieminen; Teijo I Saari; Mikko Neuvonen; Pertti J Neuvonen; Kari Laine; Klaus T Olkkola
Journal:  Eur J Clin Pharmacol       Date:  2008-10-03       Impact factor: 2.953

10.  Extended-release hydrocodone - gift or curse?

Authors:  Daniel Krashin; Natalia Murinova; Andrea M Trescot
Journal:  J Pain Res       Date:  2013-01-10       Impact factor: 3.133
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.